HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

LN950

dual inhibitor of p38MAPK and JNK3 kinases

Also Known As:

2-((5-(4-fluorophenyl)-4-(2-((3-methylbutan-2-yl)amino)pyridin-4-yl)-1H-imidazol-2-yl)thio)ethan-1-ol; LN 950; LN-950

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - LN950: 1
  - Pyridines: 88
    - LN950: 1

Experts

1.	Fuchs, Kerstin: 1 article (12/2019)
2.	Gonzalez-Menendez, Irene: 1 article (12/2019)
3.	Guenthoer, Philipp: 1 article (12/2019)
4.	Kneilling, Manfred: 1 article (12/2019)
5.	Laufer, Stefan: 1 article (12/2019)
6.	Pichler, Bernd J: 1 article (12/2019)
7.	Quintanilla-Martinez, Leticia: 1 article (12/2019)
8.	Reischl, Gerald: 1 article (12/2019)

Related Diseases

1.	Rheumatoid Arthritis 12/01/2019 - "Mitogen-activated protein kinase (MAPK) signaling plays an important role in inflammatory diseases such as rheumatoid arthritis (RA).The aim of our study was to elucidate the therapeutic potential of the highly selective p38 MAPK inhibitor Skepinone-L and the dual inhibitor LN 950 (p38 MAPK and JNK 3) in the K/BxN serum transfer model of RA. "
2.	Experimental Arthritis 12/01/2019 - "Skepinone-L and LN 950 were applicable to suppress the severity of experimental arthritis confirmed by reduced ankle swelling and histopathological analysis. " 12/01/2019 - "Both the selective p38 MAPK inhibitor Skepinone-L and the dual (p38 MAPK and JNK 3) inhibitor LN 950 exhibited significant therapeutic effects during experimental arthritis. "
3.	Arthritis (Polyarthritis) 12/01/2019 - "Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis." 12/01/2019 - "Skepinone-L (3.18 ± 0.19 mm) and LN 950 (3.40 ± 0.13 mm) treatment yielded a significantly reduced ankle thickness compared to Sham-treated mice (3.62 ± 0.11 mm) on day 5 after autoantibody transfer, a time-point characterized by severe arthritis. "

Related Drugs and Biologics

1.	p38 Mitogen-Activated Protein Kinases
2.	Mitogen-Activated Protein Kinases
3.	skepinone-L
4.	Therapeutic Uses
5.	Autoantibodies
6.	salicylhydroxamic acid (SHAM)